Walleye Capital’s Biotech Acquisition Company Unit BIOTU Stock Holding History

Walleye Capital’s Portfolio BIOTU Stock Details BIOTU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-37,192	Closed	-$369K	–	2832
2022 Q1	$369K	Buy	37,192 +12,593	+51%	+$126K	0.01%	1187
2021 Q4	$249K	Sell	24,599 -95,403	-80%	-$965K	0.01%	1358
2021 Q3	$1.21K	Buy	120,002 +2	+0%	+$20	0.03%	367
2021 Q2	$1.21K	Hold	120,000	–	–	0.04%	374
2021 Q1	$1.19K	Buy	+120,000	New	+$1.23M	0.07%	254

Other funds holding BIOTU

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Walleye Capital's BIOTU Position: Q2 2022 in Review

Walleye Capital sold out of Biotech Acquisition Company Unit (BIOTU) in Q2 2022, closing a stake of 37,192 shares — an estimated $369K sold.

Walleye Capital first reported a position in BIOTU in Q1 2021 and held it in 5 quarters. The position peaked at $369K in Q1 2022. 5 funds tracked by Wall St. Rank hold BIOTU as of Q2 2022.

Walleye Capital reported no remaining Biotech Acquisition Company Unit position as of Q2 2022 after selling out during the quarter.
Walleye Capital sold 37,192 Biotech Acquisition Company Unit shares in Q2 2022, an estimated $369K.
Walleye Capital first reported a position in Biotech Acquisition Company Unit in Q1 2021 and held it in 5 quarters.
Walleye Capital's Biotech Acquisition Company Unit position peaked at $369K in Q1 2022.
5 funds tracked by Wall St. Rank held Biotech Acquisition Company Unit as of Q2 2022.

Based on Walleye Capital's 13F filing for Q2 2022, filed 8 Aug 2022.